Nikolaos Pagonas1,2, Kourosh Yusefi3, Felix S Seibert1, Frederic Bauer1, Konstantinos Markakis1, Benjamin Sasko1,2, Walter Zidek3, Theresa Götze4, Peter Schlattmann4, Richard Viebahn5, Nina Babel1, Timm H Westhoff6. 1. Medical Department I, University Hospital Marien Hospital Herne, Ruhr University Bochum, Hölkeskampring 40, 44625, Herne, Germany. 2. Department of Cardiology and Angiology, Medical University Brandenburg, Brandenburg, Germany. 3. Department of Nephrology, Charité-Campus Benjamin Franklin, Berlin, Germany. 4. Department of Medical Statistics, Informatics and Documentation, Jena University Hospital, Jena, Germany. 5. Department of Surgery, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany. 6. Medical Department I, University Hospital Marien Hospital Herne, Ruhr University Bochum, Hölkeskampring 40, 44625, Herne, Germany. timm.westhoff@elisabethgruppe.de.
Abstract
OBJECTIVE: Attempts to discontinue calcineurin inhibitors (CNIs) early after renal transplantation without conversion to an alternative immunosuppressive have failed due to high rates of acute rejection. Data on "late" CNI withdrawal are lacking so far. DESIGN AND METHOD: We carried out a matched case-control study on the effects of CNI withdrawal on graft loss and mortality in 90 patients (1500 screened) with advanced graft dysfunction (serum creatinine > 3.5 mg/dl) and a cyclosporine-based triple immunosuppressive regimen at the Charité University Hospital, Berlin. RESULTS: Cyclosporine was withdrawn at a mean of 54.0 ± 32.8 months post-transplant in 45 subjects. Whereas estimated glomerular filtration rate (eGFR) did not significantly differ between the groups at this time (12.4 ± 2.7 vs. 14.7 ± 8.9 in the control group, p = 0.08), it was significantly higher in subjects undergoing withdrawal after 120 months (Δ 4.1 ml/min; p < 0.001). In a Cox regression analysis adjusted for age, gender and eGFR, patients with CNI withdrawal showed better survival rates for the combined endpoint death/graft loss (hazard ratio, HR [95% confidence interval]: 0.19 [0.12-0.33], p = 0.001) compared to matched controls. The survival benefit was significant for the endpoints death (p = 0.01) and graft loss (p = 0.001). CONCLUSIONS: CNI withdrawal was associated with improved survival rates in patients with advanced graft dysfunction in this retrospective analysis.
OBJECTIVE: Attempts to discontinue calcineurin inhibitors (CNIs) early after renal transplantation without conversion to an alternative immunosuppressive have failed due to high rates of acute rejection. Data on "late" CNI withdrawal are lacking so far. DESIGN AND METHOD: We carried out a matched case-control study on the effects of CNI withdrawal on graft loss and mortality in 90 patients (1500 screened) with advanced graft dysfunction (serum creatinine > 3.5 mg/dl) and a cyclosporine-based triple immunosuppressive regimen at the Charité University Hospital, Berlin. RESULTS:Cyclosporine was withdrawn at a mean of 54.0 ± 32.8 months post-transplant in 45 subjects. Whereas estimated glomerular filtration rate (eGFR) did not significantly differ between the groups at this time (12.4 ± 2.7 vs. 14.7 ± 8.9 in the control group, p = 0.08), it was significantly higher in subjects undergoing withdrawal after 120 months (Δ 4.1 ml/min; p < 0.001). In a Cox regression analysis adjusted for age, gender and eGFR, patients with CNI withdrawal showed better survival rates for the combined endpoint death/graft loss (hazard ratio, HR [95% confidence interval]: 0.19 [0.12-0.33], p = 0.001) compared to matched controls. The survival benefit was significant for the endpoints death (p = 0.01) and graft loss (p = 0.001). CONCLUSIONS: CNI withdrawal was associated with improved survival rates in patients with advanced graft dysfunction in this retrospective analysis.
Authors: H Ekberg; J Grinyó; B Nashan; Y Vanrenterghem; F Vincenti; A Voulgari; M Truman; C Nasmyth-Miller; M Rashford Journal: Am J Transplant Date: 2007-01-22 Impact factor: 8.086
Authors: Brian J Nankivell; Richard J Borrows; Caroline L S Fung; Philip J O'Connell; Jeremy R Chapman; Richard D M Allen Journal: Transplantation Date: 2004-08-27 Impact factor: 4.939
Authors: Roberto Marcén; José María Morales; Ana Fernández-Rodriguez; Luis Capdevila; Luis Pallardó; Juan José Plaza; Juan José Cubero; Josep María Puig; Ana Sanchez-Fructuoso; Manual Arias; Gabriela Alperovich; Daniel Serón Journal: NDT Plus Date: 2010-06
Authors: Francesco P Schena; Michael D Pascoe; Josefina Alberu; Maria del Carmen Rial; Rainer Oberbauer; Daniel C Brennan; Josep M Campistol; Lorraine Racusen; Martin S Polinsky; Robert Goldberg-Alberts; Huihua Li; Joseph Scarola; John F Neylan Journal: Transplantation Date: 2009-01-27 Impact factor: 4.939
Authors: Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245